Medline ® Abstract for Reference 76
of 'Infusion reactions to systemic chemotherapy'
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.
Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN
Int Arch Allergy Immunol. 2011;156(3):320. Epub 2011 Jun 29.
BACKGROUND: Docetaxel (DT) is an extensively used taxane, frequently associated with hypersensitivity reactions. The aim of this study was to record the epidemiological and clinical features of hypersensitivity to DT in non-small cell lung cancer patients in order to obtain useful information concerning the management of these patients. We also developed a desensitization protocol and evaluated its clinical application.
METHODS: We retrospectively reviewed records of 620 non-small cell lung cancer patients treated with DT-containing regimens in the adjuvant, first-, second- or next-line setting. Data from 102 patients who had exhibited hypersensitivity reactions were analyzed according to the Common Toxicity Criteria for Adverse Events version 3.0. Five patients were chosen for the desensitization protocol. We applied the standard protocol for parenteral desensitization toβ-lactam antibiotics, and DT treatment was carried out with a series of 10-fold dilutions in sufficient volume to administer the total dose.
RESULTS: One hundred and two patients (16.5%) were recorded as having hypersensitivity to DT. Reactions were observed after approximately 2.5±1.0 cycles. Only 14 patients (14/620, 2%) developed grade 3-4 hypersensitivity. Reactions were more likely in patients during second- or third-line chemotherapy, but no other correlation (age, gender, atopic status) was observed. Five patients completed a parenteral desensitization protocol and continued their treatment uneventfully.
CONCLUSIONS: Hypersensitivity reactions to DT respond quickly to discontinuation along with appropriate supportive care. Premedication and increased infusion time may allow readministration. The desensitization protocol that we developed provides a reliable alternative to permanent discontinuation of DT.
Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece.